← BioArctic AB Series B overview

BioArctic AB Series B vs Haleon: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

BioArctic AB Series B (0RV2.LSE)

Q3 2026
▲3

Lilly deal, Leqembi at-home approval and 43% royalty growth lift BioArctic

  • Lilly BrainTransporter deal brings $30M upfront and up to $770M milestones BioArctic signed a research deal with Eli Lilly combining its BrainTransporter brain-delivery technology with a Lilly neurodegeneration drug. It gets $30 million cash now and could receive up to $770 million more if milestones are met, plus royalties on future sales. This is the fourth such partnership, showing the technology is valued by big drugmakers.

    New cash and validation of the BrainTransporter platform directly improve BioArctic's finances and future earnings potential.

  • FDA approves at-home Leqembi autoinjector as starting dose US regulators approved a once-weekly under-the-skin Leqembi injection, given at home with an autoinjector, as a starting treatment for early Alzheimer's. Patients no longer need clinic infusions to begin therapy. Easier use should widen the number of patients who start and stay on the drug, lifting BioArctic's royalties.

    Broader and simpler access to Leqembi is the main long-term driver of BioArctic's royalty income.

  • Leqembi royalties up about 43% excluding one-off China stockpiling Leqembi global sales were 29.3 billion yen in Q2 2026, paying BioArctic 179 million Swedish kronor in royalties. That is about 10% higher than a year earlier, but last year included a one-time China stockpiling boost; stripping that out, royalties grew roughly 43%. Underlying demand for the drug is clearly rising.

    Royalty income is BioArctic's recurring revenue base, so its underlying growth rate is central to the investment case.

  • Q2 results show growing royalties but still a small operating loss BioArctic's Q2 revenue was 247.5 million kronor, mostly Leqembi royalties, but it still posted a small operating loss of 6.5 million kronor and a loss per share of 0.13 kronor. It also began an oncology collaboration with Mesenkia on a glioblastoma antibody treatment. Cash from Lilly and rising royalties fund research, but profits have not yet arrived.

    It shows the real counterweight: strong deal and royalty momentum, yet the company is not yet profitable.

July 2026
▲3

Lilly deal, Leqembi at-home approval and 43% royalty growth lift BioArctic

  • Lilly BrainTransporter deal brings $30M upfront and up to $770M milestones BioArctic signed a research deal with Eli Lilly combining its BrainTransporter brain-delivery technology with a Lilly neurodegeneration drug. It gets $30 million cash now and could receive up to $770 million more if milestones are met, plus royalties on future sales. This is the fourth such partnership, showing the technology is valued by big drugmakers.

    New cash and validation of the BrainTransporter platform directly improve BioArctic's finances and future earnings potential.

  • FDA approves at-home Leqembi autoinjector as starting dose US regulators approved a once-weekly under-the-skin Leqembi injection, given at home with an autoinjector, as a starting treatment for early Alzheimer's. Patients no longer need clinic infusions to begin therapy. Easier use should widen the number of patients who start and stay on the drug, lifting BioArctic's royalties.

    Broader and simpler access to Leqembi is the main long-term driver of BioArctic's royalty income.

  • Leqembi royalties up about 43% excluding one-off China stockpiling Leqembi global sales were 29.3 billion yen in Q2 2026, paying BioArctic 179 million Swedish kronor in royalties. That is about 10% higher than a year earlier, but last year included a one-time China stockpiling boost; stripping that out, royalties grew roughly 43%. Underlying demand for the drug is clearly rising.

    Royalty income is BioArctic's recurring revenue base, so its underlying growth rate is central to the investment case.

  • Q2 results show growing royalties but still a small operating loss BioArctic's Q2 revenue was 247.5 million kronor, mostly Leqembi royalties, but it still posted a small operating loss of 6.5 million kronor and a loss per share of 0.13 kronor. It also began an oncology collaboration with Mesenkia on a glioblastoma antibody treatment. Cash from Lilly and rising royalties fund research, but profits have not yet arrived.

    It shows the real counterweight: strong deal and royalty momentum, yet the company is not yet profitable.

Latest
▲3

Lilly deal, Leqembi at-home approval and 43% royalty growth lift BioArctic

  • Lilly BrainTransporter deal brings $30M upfront and up to $770M milestones BioArctic signed a research deal with Eli Lilly combining its BrainTransporter brain-delivery technology with a Lilly neurodegeneration drug. It gets $30 million cash now and could receive up to $770 million more if milestones are met, plus royalties on future sales. This is the fourth such partnership, showing the technology is valued by big drugmakers.

    New cash and validation of the BrainTransporter platform directly improve BioArctic's finances and future earnings potential.

  • FDA approves at-home Leqembi autoinjector as starting dose US regulators approved a once-weekly under-the-skin Leqembi injection, given at home with an autoinjector, as a starting treatment for early Alzheimer's. Patients no longer need clinic infusions to begin therapy. Easier use should widen the number of patients who start and stay on the drug, lifting BioArctic's royalties.

    Broader and simpler access to Leqembi is the main long-term driver of BioArctic's royalty income.

  • Leqembi royalties up about 43% excluding one-off China stockpiling Leqembi global sales were 29.3 billion yen in Q2 2026, paying BioArctic 179 million Swedish kronor in royalties. That is about 10% higher than a year earlier, but last year included a one-time China stockpiling boost; stripping that out, royalties grew roughly 43%. Underlying demand for the drug is clearly rising.

    Royalty income is BioArctic's recurring revenue base, so its underlying growth rate is central to the investment case.

  • Q2 results show growing royalties but still a small operating loss BioArctic's Q2 revenue was 247.5 million kronor, mostly Leqembi royalties, but it still posted a small operating loss of 6.5 million kronor and a loss per share of 0.13 kronor. It also began an oncology collaboration with Mesenkia on a glioblastoma antibody treatment. Cash from Lilly and rising royalties fund research, but profits have not yet arrived.

    It shows the real counterweight: strong deal and royalty momentum, yet the company is not yet profitable.

Haleon PLC (HLN.LSE)

Q3 2026
▲2▼1

Haleon buys US shelf space and GLP-1 tie-ins to lift growth

  • US shelf-space wins lift market share Haleon won prime shelf spots at Walmart and Target by offering lower prices and promotions, lifting its US consumer-health share from 11.4% to 12%. More visibility for Sensodyne and Centrum should support sales, though the profit cost of those deals is undisclosed.

    This is the main new force behind Haleon's US growth push and share gains.

  • GLP-1 side-effect products drive store sales Haleon's products for GLP-1 weight-loss drug side effects, placed in dedicated CVS sections, produced an average 24% sales lift per store. With about 11% of Americans using GLP-1 drugs, this opens a new demand channel and talks are underway with Walmart and Target.

    It shows a fresh, measurable sales driver tied to a fast-growing consumer trend.

  • First-half profit beat but sales growth lags Haleon beat profit expectations and raised its dividend, but organic revenue growth of 2.6% is below its 4%-6% medium-term target, with weak European demand and a 6.5% drop in respiratory sales. Shares fell as investors doubted the sales outlook.

    It captures the core tension: solid earnings versus sluggish underlying sales growth.

  • Debt buyback uses cash and adds costs Haleon repurchased $1.34 billion of 2027 notes at a premium, reducing future debt but using cash and incurring costs. This is a minor capital-structure move that slightly weighs on near-term financial flexibility.

    It is a new capital action that affects Haleon's cash position and debt profile.

August 2026
▲2▼1

Haleon buys US shelf space and GLP-1 tie-ins to lift growth

  • US shelf-space wins lift market share Haleon won prime shelf spots at Walmart and Target by offering lower prices and promotions, lifting its US consumer-health share from 11.4% to 12%. More visibility for Sensodyne and Centrum should support sales, though the profit cost of those deals is undisclosed.

    This is the main new force behind Haleon's US growth push and share gains.

  • GLP-1 side-effect products drive store sales Haleon's products for GLP-1 weight-loss drug side effects, placed in dedicated CVS sections, produced an average 24% sales lift per store. With about 11% of Americans using GLP-1 drugs, this opens a new demand channel and talks are underway with Walmart and Target.

    It shows a fresh, measurable sales driver tied to a fast-growing consumer trend.

  • First-half profit beat but sales growth lags Haleon beat profit expectations and raised its dividend, but organic revenue growth of 2.6% is below its 4%-6% medium-term target, with weak European demand and a 6.5% drop in respiratory sales. Shares fell as investors doubted the sales outlook.

    It captures the core tension: solid earnings versus sluggish underlying sales growth.

  • Debt buyback uses cash and adds costs Haleon repurchased $1.34 billion of 2027 notes at a premium, reducing future debt but using cash and incurring costs. This is a minor capital-structure move that slightly weighs on near-term financial flexibility.

    It is a new capital action that affects Haleon's cash position and debt profile.

Latest
▲2▼1

Haleon buys US shelf space and GLP-1 tie-ins to lift growth

  • US shelf-space wins lift market share Haleon won prime shelf spots at Walmart and Target by offering lower prices and promotions, lifting its US consumer-health share from 11.4% to 12%. More visibility for Sensodyne and Centrum should support sales, though the profit cost of those deals is undisclosed.

    This is the main new force behind Haleon's US growth push and share gains.

  • GLP-1 side-effect products drive store sales Haleon's products for GLP-1 weight-loss drug side effects, placed in dedicated CVS sections, produced an average 24% sales lift per store. With about 11% of Americans using GLP-1 drugs, this opens a new demand channel and talks are underway with Walmart and Target.

    It shows a fresh, measurable sales driver tied to a fast-growing consumer trend.

  • First-half profit beat but sales growth lags Haleon beat profit expectations and raised its dividend, but organic revenue growth of 2.6% is below its 4%-6% medium-term target, with weak European demand and a 6.5% drop in respiratory sales. Shares fell as investors doubted the sales outlook.

    It captures the core tension: solid earnings versus sluggish underlying sales growth.

  • Debt buyback uses cash and adds costs Haleon repurchased $1.34 billion of 2027 notes at a premium, reducing future debt but using cash and incurring costs. This is a minor capital-structure move that slightly weighs on near-term financial flexibility.

    It is a new capital action that affects Haleon's cash position and debt profile.